T Lymphocytes

Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells
Martin J Lett, Hema Mehta, Adrian Keogh, Tina Jaeger, Maxime Jacquet, Kate Powell, Marie-Anne Meier, Isabel Fofana, Hassan Melhem, Jürg Vosbeck, Gieri Cathomas, Andres Heigl, Markus H Heim, Emanuel Burri, Kirsten D Mertz, Jan Hendrik Niess, Otto Kollmar, Christoph J Zech, Robert Ivanek, Urs Duthaler, Paul Klenerman, Deborah Stroka, Magdalena Filipowicz Sinnreich

Gut Dec 2022, 71 (12) 2526-2538; DOI: 10.1136/gutjnl-2021-324478
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model
Sumit Kumar, Mark J A Schoonderwoerd, Jessie S Kroonen, Ilona J de Graaf, Marjolein Sluijter, Dina Ruano, Román González-Prieto, Matty Verlaan-de Vries, Jasper Rip, Ramon Arens, Noel F C C de Miranda, Lukas J A C Hawinkels, Thorbald van Hall, Alfred C O Vertegaal

Gut Nov 2022, 71 (11) 2266-2283; DOI: 10.1136/gutjnl-2021-324834
Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
Elmira Aliabadi, Melanie Urbanek-Quaing, Benjamin Maasoumy, Birgit Bremer, Martin Grasshoff, Yang Li, Christian E Niehaus, Heiner Wedemeyer, Anke R M Kraft, Markus Cornberg

Gut Nov 2022, 71 (11) 2300-2312; DOI: 10.1136/gutjnl-2021-324646
Immunopathogenesis and environmental triggers in coeliac disease
Anais Levescot, Georgia Malamut, Nadine Cerf-Bensussan

Gut Nov 2022, 71 (11) 2337-2349; DOI: 10.1136/gutjnl-2021-326257
Residual homing of α4β7-expressing β1⁺PI16⁺ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab
Emily Becker, Mark Dedden, Christine Gall, Maximilian Wiendl, Arif Bülent Ekici, Anja Schulz-Kuhnt, Anna Schweda, Caroline Voskens, Ahmed Hegazy, Francesco Vitali, Raja Atreya, Tanja Martina Müller, Imke Atreya, Markus F Neurath, Sebastian Zundler

Gut Aug 2022, 71 (8) 1551-1566; DOI: 10.1136/gutjnl-2021-324868
Deciphering the vedolizumab dosing conundrum in IBD: when less is more
Timon Erik Adolph, Britta Siegmund

Gut Aug 2022, 71 (8) 1455-1456; DOI: 10.1136/gutjnl-2021-325893
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection
Kathrin Heim, Benedikt Binder, Sagar, Dominik Wieland, Nina Hensel, Sian Llewellyn-Lacey, Emma Gostick, David A. Price, Florian Emmerich, Hildegard Vingerhoet, Anke R M Kraft, Markus Cornberg, Tobias Boettler, Christoph Neumann-Haefelin, Dietmar Zehn, Bertram Bengsch, Maike Hofmann, Robert Thimme

Gut Aug 2021, 70 (8) 1550-1560; DOI: 10.1136/gutjnl-2020-322404
Increased expression of IL-16 in inflammatory bowel disease
D Seegert, P Rosenstiel, H Pfahler, P Pfefferkorn, S Nikolaus, S Schreiber

Gut Mar 2001, 48 (3) 326-332; DOI: 10.1136/gut.48.3.326
Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acuteCampylobacter enteritis and in post-dysenteric irritable bowel syndrome
R C Spiller, D Jenkins, J P Thornley, J M Hebden, T Wright, M Skinner, K R Neal

Gut Dec 2000, 47 (6) 804-811; DOI: 10.1136/gut.47.6.804
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39⁺CD8⁺ T cells
Ting Liu, Jizhou Tan, Minhao Wu, Wenzhe Fan, Jialiang Wei, Bowen Zhu, Jian Guo, Shutong Wang, Penghui Zhou, Hui Zhang, Liangrong Shi, Jiaping Li

Gut Oct 2021, 70 (10) 1965-1977; DOI: 10.1136/gutjnl-2020-322196

Main menu

T Lymphocytes

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

T Lymphocytes

Pages